Australian antiviral drug development company Island Pharmaceuticals has reallocated US government funding to support its planned ISLA-101 Phase 2a human clinical trial in dengue fever.
Sponsored
New Stories
-
Island announces reallocation of US grant funding to support den
May 8, 2024 - - AusBiotech -
Echo IQ submits application seeking FDA approval of AI-supported heart diagnostic
May 7, 2024 - - Latest News -
TGA seeks nominations for statutory advisory committees
May 7, 2024 - - AusBiotech -
PolyNovo announces appointment of general counsel and company secretary
May 7, 2024 - - Latest News -
Scholarships open for supporting women into STEM careers
May 7, 2024 - - Latest News -
CUREator deploys $7.21 Million to propel local life sciences potential
May 7, 2024 - - Latest News -
Industry applauds funding commitment for National One Stop Shop for clinical trials
May 2, 2024 - - AusBiotech